Kiora Pharmaceuticals (KPRX) FCF Margin (2016 - 2024)

Kiora Pharmaceuticals' (KPRX) quarterly FCF Margin came in at 18667.2% in Q2 2024, down 22021.34% quarter-over-quarter from 85.16% in Q1 2024.

Analysis

Kiora Pharmaceuticals (KPRX) FCF Margin (2016 - 2024) Analysis & Trends

Kiora Pharmaceuticals (KPRX) has reported FCF Margin for 6 consecutive years, with 18667.2% the latest figure, recorded in Q2 2024.

For the quarter ending Q2 2024, FCF Margin changed N/A year-over-year to 18667.2%; the trailing twelve-month figure through Mar 2025 stood at 38624.54% (down 3866915.0% YoY), and the FY2024 full-year result was 53.39%, changed N/A from the prior year.
FCF Margin retreated to 18667.2% in Q2 2024 per KPRX's latest filing, from 85.16% in the prior quarter.
Across five years, FCF Margin topped out at 85.16% in Q1 2024 and bottomed at 18667.2% in Q2 2024.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	FCF Margin (Qtr)
1	Johnson & Johnson	663.08 Bn	642.33 Bn	17.26 Bn	28.82%
2	AbbVie	453.04 Bn	446.51 Bn	12.70 Bn	18.33%
3	Merck	370.87 Bn	363.78 Bn	12.21 Bn	26.96%
4	Novartis Ag	305.29 Bn	298.00 Bn	11.24 Bn	43.05%
5	Pfizer	162.10 Bn	150.70 Bn	10.94 Bn	2.01%
6	Sanofi	53.95 Bn	46.98 Bn	10.79 Bn	25.52%
7	Revolution Medicines	45.00 Bn	45.00 Bn	-	-
8	Incyte	25.47 Bn	20.94 Bn	1.57 Bn	29.58%
9	United Therapeutics	20.81 Bn	18.15 Bn	683.80 Mn	26.25%
10	Kiora Pharmaceuticals	15.75 Mn	15.75 Mn	-	-

Historic Data

Download Data